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I have been presented with a significant challenge, having been asked to discuss
how genomics, specifically medical genomics, is being integrated into medical
practice at the Mayo Clinic, a tertiary care, a highly scientific, and—if you
are␣ familiar with the people who are there—a very formal type of institution.
I␣ will explain the approach we are taking to provide some insight into:
• how an institution like the Mayo Clinic tries to assimilate new information
that’s important in diagnosis and treatment, but yet somewhat problematic
for the physicians involved, and
• the possibility that there are overlapping areas of interest between
nutraceuticals and the effects of diet on health, and genomics.
I believe that diet has very strong effects on health. I believe that it is also
true that disease is almost exclusively determined by genes and abnormalities
in␣ genes. I don’t think that these are contradictory positions, and I think
that␣ the challenge for conference attendees, and the challenge for those of
us␣ who are more classically interested researchers, is to find areas of overlap.
Sequencing of the human genome has had a profound impact in the medical
community. The effects have been to focus attention on medical genomics,
and␣ it is clear that there are significant implications for clinical practice.
EVOLUTION OF MEDICAL GENOMICS
Major advances in medical genomics began in the late 1940s and the 50s with
progress in genetics, and with genetic engineering in the 1970s. The human-
genome project represented a major conceptual step forward, and when it was
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completed, it was clear that there was tremendous potential for impact on the
diagnosis and treatment of disease. This new information will gain entrance
to␣ medical practice through cardiomics and bioinformatics, and will assist in
the diagnosis of disease, the identification of diseases in relation to genes, the
identification of predisposition to disease, the identification of new therapeu-
tics, and understanding of individual responses of particular patients to
particular therapeutics.
The key then is that using the new medical-genomics information is going to
transform diagnosis, therapy, and treatment, and approaches to predisposition
to disease in practices such as we have at the Mayo Clinic.
We have always known that some diseases are genetic, or have a genetic
component. Since the early ’90s, there has been an exponential increase in the
identification of diseases that have a strong genetic contribution. There has
been, as another example, quite a bit of interest in pharmacogenomics, where
it␣ has been determined that specific genes or specific polymorphisms in genes
will determine the response of a particular individual to a drug. Why, for
example, will one person take aspirin and have success in treating their arthritic
pain, while another patient will not? The most likely answer is that differences
in the genes that those patients have determine those variable responses.
Along with these opportunities, however, there are challenges and, indeed,
problems. The potential exists for a loss of patient privacy and confidentiality
of␣ medical information, which is of concern to all physicians in all institutions.
There is also the potential for a loss of control on the part of the patient
over␣ their medical care. Some would argue that this is already occurring.
The␣ potential is certainly there for this to get worse. Discrimination on the
basis␣ of genetics and on the basis of finances is, of course, real. Expectations
are␣ going to change from the physician perspective in a way that is unpredict-
able, and, unfortunately, as it always has been in the past, more-technical
medical care will be associated with much higher costs.
MAYO’S MISSION
These changes and opportunities are reflected in our mission statement,
“The␣ Mayo Clinic prides itself in its ability to elucidate the goals that it has,”
and one of the current major goals is to include genomics in the integrated
practice of medicine. The difficulty is that for the majority of physicians there
is␣ very little understanding of genetics, little understanding of its principals,
little understanding of the practice, and little understanding of the tests. And
so␣ the challenge for the individual physician, for the clinic, and for the medical
community at large, is to develop paradigms and opportunities to educate
physicians in practice about the new opportunities, and also the new
responsibilities and problems.
The guiding principal at our institution is that all physicians, not just
medical geneticists as a subspecialty, but all physicians can participate in this
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process. But without a strong knowledge base, to achieve that goal is going
to␣ require a significant educational effort. To achieve this educational effort
a␣ Genomics Education Steering Committee was formed with three goals
and␣ charges:
• to transmit information to all physicians of the clinic,
• to transmit to the clinicians the significance and importance of this
information, and
• to develop an educational plan to maintain the standards of education
and␣ the standards of care.
The group, of which I am a member, has initiated efforts in several areas.
There has been provision of resources, primarily on a Web-site. There have
been educational activities, including seminars. There is also coordination of
research activities at the clinic, which is being done in consultation with the
communications department.
One of the first things that we did as a committee was assay the level of
knowledge and the level of comfort of our physicians with genomic tests and
with ethical, legal, and social issues, termed “elsi.” Interestingly, a high number
of the physicians were not at all comfortable. As a corollary, a high number of
physicians expressed strong desire for educational materials, reinforcing our
initial concept of both a strong need for education and also a very good
opportunity for education.
There has been significant activity in continuing education. We have
organized a large number of lectures and several symposiums, videos are
available to physicians and we are coordinating activities with allied health
staff. We will continue these activities to bring new genomics information
to␣ our clinicians. We have given a major introductory course on medical
genomics, in which a large number of people from the committee participated.
We are planning a major continuing educational course; Alan Bradley,
the␣ director of one of the major genome-sequencing centers in the world,
the␣ Welcome Sander Center in the UK, will be our keynote speaker.
We have also put together as a second area of activity, a group of interested
faculty members who are supporting the effort as liaisons between our
committee and the different departments and committees. Clearly there is
a␣ need for information that is specific for particular physicians’ practices or
the␣ practice of a particular group or division. And, by identifying interested
individuals in each group, we hope to facilitate the educational process.
We have put together a web site, which, unfortunately, is not yet available
outside the clinic. We are working diligently to construct something that will
be␣ transportable and will be usable by physicians other than those at the clinic.
As the director of this process, I have to say that this is an incredibly time-
consuming and resource-consuming activity, and it will be some time before
we␣ will be fully operational.
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THE CHALLENGE
In conclusion, the Mayo Clinic is engaged in what I think is reasonably termed
an aggressive effort to prepare the staff and the allied healthcare for changes in
medicine, with genomics and medical genomics becoming a central part of the
therapies that we will offer. To reach this goal, to effect this education, we are
expending effort as I’ve described, we are identifying key staff developing web
sites and supporting material for those individuals.
This is a little different from the interests of most of those attending this
conference, but I would stress the need for integration of the new genomics
information, new nutraceuticals information and foods-for-health information
towards a more comprehensive understanding of health and of disease. That’s a
challenge for all of us.
